Cure Duchenne appoints Michael Kelly as Chief Scientific Officer
CureDuchenne, a national nonprofit that funds research to find a cure for Duchenne muscular dystrophy, today announced the appointment of Dr. Michael G. Kelly as Chief Scientific Officer, a key scientific position within the Duchenne community. Kelly, a senior pharmaceutical executive, brings more than 25 years experience in drug discovery and development to the organization. He will help advance drug development programs and help identify new drug targets that exhibit potential to transform the treatment of Duchenne muscular dystrophy.
In addition, Kelly will be responsible for CureDuchenne’s Drug Discovery and Development Program to help drive research to market for treatments and ultimately a cure for Duchenne. Before joining CureDuchenne, Kelly served as President and U.S. site head of Renovis, Inc. and has held senior positions at Amgen, Inc., Wyeth (Pfizer) and Wellcome (GlaxoSmithKline).
Kelly holds a PhD from the University of Southampton (U.K.), held research positions at the University of Michigan and University of Nottingham, is an inventor on more than 100 patents and is widely published in peer reviewed journals.